FOR INDUSTRY
PARTNERS

What could you do with patient-consented, regulatory-grade, real-world patient data? ROOT brings unprecedented value to all stakeholders in cancer care.

THE REALITY
Faster identification of patients for clinical trials can shorten drug development and time-to-market—resulting in efficiency and value.

WHAT WE DELIVER
Once drugs are ready for testing, companies can use our network and database to find the exact patients to populate clinical trials. Depending on the rarity of the cancer, this could shave years off the selection process.

THE REALITY
Researchers need better access to patients with specific cancer data, including pathology, staging, biomarkers, genomic sequencing, radiology and treatment.

WHAT WE DELIVER
Research-quality data that meets rigorous scientific standards can help researchers conduct complex studies, publish in shorter time frames and strengthen their opportunities for grant funding.

THE REALITY
Laboratories need evidence of clinical benefit of testing before they can receive payor coverage.

WHAT WE DELIVER
A database that matches diagnostic data, treatment details, and outcomes that provide the necessary evidence to prove that a new test is clinically valuable, biologically sound, and scientifically validated.

THE REALITY
Most companies are using synthetic data, which generates poor results.

WHAT WE DELIVER
Standardized, high-quality and real (not synthetic) patient clinical data can help companies generate meaningful information and move medicine forward through predictive outcomes and new models for drug discovery.

THE REALITY
By aligning with Taproot Health, investors become catalysts for a new era in precision oncology—moving the world toward personalized care.

WHAT WE DELIVER
By providing a one-stop resource for data—plus a unique revenue-sharing model that motivates physician participation—Taproot Health is disrupting traditional data models, challenging the status quo, and setting a new standard with the next generation of data-as-a-service (DaaS) model.